NCT04191005

Brief Summary

assess the literature on PRP outcomes for AGA, with a focus on specific clinical outcomes in a comparative view, in accordance with PRISMA statement for reporting this meta-analysis

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
15

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jan 2020

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 4, 2019

Completed
5 days until next milestone

First Posted

Study publicly available on registry

December 9, 2019

Completed
29 days until next milestone

Study Start

First participant enrolled

January 7, 2020

Completed
13 days until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 20, 2020

Completed
10 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 30, 2020

Completed
Last Updated

January 7, 2020

Status Verified

January 1, 2020

Enrollment Period

13 days

First QC Date

December 4, 2019

Last Update Submit

January 6, 2020

Conditions

Androgenetic Alopecia

Outcome Measures

Primary Outcomes (1)

  • number of hair per square centimeter

    measure the number of hairs per square centimeter.

    one year

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Data will be abstracted from every study in the form of a risk estimate and its 95% confidence interval (C1). Pooled risk estimate will be obtained by weighting each study by the inverse variance of the effect measure on algorithmic scale. This approach to pooling the results assumes that the study population being compared are similar and hence correspond to affixed effect analysis. The validity of pooling the risk estimate will be tested (test of homogeneity) using the chi-square test. A violation of this test implies that the studies being grouped differ from one another. In the presence of significant heterogeneity of the effect measure among studies being compared,

You may qualify if:

  • Search for and assess studies comparing local injections of PRP compared to any control for AGA.
  • Studies to be included in this review will be matched with predetermined criteria according to the PICOS (patients, intervention, comparator, outcomes, and study design) approach.
  • These studies must include patients with any age and stage of AGA , with a minimum of 10 patients, a minimum of 3 months follow -up.
  • Local injection of any autologous of PRP preparation into the scalp of AGA patients for treatment of AGA.
  • Measure the efficacy of PRP therapy for treatment of AGA.

You may not qualify if:

  • Review, expert opinion, comments, letter to editor, case reports, studies on animals, conference reports will be excluded from the study.
  • Studies of other types of alopecia (i.e., alopecia areata or cicatricial alopecia) or studies with less than 10 patients, follow up less than 3 months or with no outcome reported, will be excluded from the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Assiut University

Asyut, Assiut Governorate, 71515 Assiut, Egypt

RECRUITING

Related Publications (4)

  • Severi G, Sinclair R, Hopper JL, English DR, McCredie MR, Boyle P, Giles GG. Androgenetic alopecia in men aged 40-69 years: prevalence and risk factors. Br J Dermatol. 2003 Dec;149(6):1207-13. doi: 10.1111/j.1365-2133.2003.05565.x.

    PMID: 14674898BACKGROUND

  • Varothai S, Bergfeld WF. Androgenetic alopecia: an evidence-based treatment update. Am J Clin Dermatol. 2014 Jul;15(3):217-30. doi: 10.1007/s40257-014-0077-5.

    PMID: 24848508BACKGROUND

  • Norwood OT. Male pattern baldness: classification and incidence. South Med J. 1975 Nov;68(11):1359-65. doi: 10.1097/00007611-197511000-00009.

    PMID: 1188424BACKGROUND

  • Stevens J, Khetarpal S. Platelet-rich plasma for androgenetic alopecia: A review of the literature and proposed treatment protocol. Int J Womens Dermatol. 2018 Sep 21;5(1):46-51. doi: 10.1016/j.ijwd.2018.08.004. eCollection 2019 Feb.

    PMID: 30809579BACKGROUND

Related Links

MeSH Terms

Conditions

Alopecia

Condition Hierarchy (Ancestors)

HypotrichosisHair DiseasesSkin DiseasesSkin and Connective Tissue DiseasesPathological Conditions, AnatomicalPathological Conditions, Signs and Symptoms

Study Officials

  • Manal mohamed Darwish, ass.professor

    community medicine

    STUDY DIRECTOR

  • Rofaida refaat Shahata, doctor

    dermatology

    PRINCIPAL INVESTIGATOR

Central Study Contacts

jasim mohamed alshammari, MSc

CONTACT

01010730962drjasimmohamed12@gmail.com

Emad abdelrahem Taha, professor

CONTACT

01006462294Emadtaha76@yahoo.com

Study Design

Study Type
observational
Observational Model
OTHER
Time Perspective
OTHER
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
director

Study Record Dates

First Submitted

December 4, 2019

First Posted

December 9, 2019

Study Start

January 7, 2020

Primary Completion

January 20, 2020

Study Completion

January 30, 2020

Last Updated

January 7, 2020

Record last verified: 2020-01

Locations

EG(1)